Cited by 239Treatment of Major DepressionNeuroscience and Neuropharmacology ResearchTryptophan and brain disorders

From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders

Open access
Sanacora, Gerard, Banasr, Mounira·2013·Biological Psychiatry

Abstract

Several structural and cellular changes, including marked glial anomalies, have been observed in association with major depressive disorder. Here we review these cellular alterations and highlight the importance of glial cell pathology, especially astroglial dysfunction, in the pathophysiology of neuropsychiatric disorders with a particular interest in major depressive disorder. The functional role of astrocytes in glutamate uptake and glutamate/glutamine cycling is discussed, as is the deleterious effects of chronic stress on glial cell function. Lastly, we discuss the effect of antidepressants on glial cell function and the possibility of targeting glial cells in the quest to develop novel therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2013.03.032

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Human postmortem studies show lower expression of several astrocyte-function components, mainly in the medial prefrontal cortex and somewhat in the hippocampus, suggesting impaired glutamate-glutamine cycling.

    “Several human postmortem studies have also shown reductions in the expression of several components critical to astrocyte function, largely in the mPFC, but also some evidence in the hippocampus, suggesting impaired glutamate-glutamine cycling (133).”
  • Emerging evidence indicates impaired glutamate-glutamine cycling in the medial prefrontal cortex and hippocampus in people with major depressive disorder.

    “There is also emerging evidence of impaired glutamate-glutamine cycling in the mPFC and hippocampus amongst those with MDD.”
  • Subjects with depression display reduced glial density, decreased expression of glutamate reuptake transporters EAAT1 and EAAT2, and decreased enzymatic conversion from glutamate to glutamine.

    “Subjects with depression have been shown to display a variety of glutamatergic abnormalities, including reduced glial density, decreased expression of the glutamate reuptake transporters EAAT1 and EAAT2 and decreased enzymatic conversion from glutamate to glutamine [33].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [3]Virchow RLK 1858 Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre Berlin A. Hirschwald 21513178

Cited by

Sorted by citations

Authors
Sanacora, G., & Banasr, M.
Affiliations
Yale University (US)
Corresponding author
Sanacora, Gerard
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2013-06
Volume
73
Issue
12
Pages
1172-1179
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2077129553
Cited by
239
References
102
Citations by year
2026: 13 · 2025: 10 · 2024: 14 · 2023: 17 · 2022: 17 · 2021: 22 · 2020: 15 · 2019: 20 · 2018: 21 · 2017: 18 · 2016: 17 · 2015: 27 · 2014: 24 · 2013: 4
FWCI
3.03
Type
journal article
Language
en
Open access
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (R01MH085055, R01MH081211, R01 MH08055)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
glial cells, astrocytes, major depressive disorder, mood disorders, glutamate uptake, chronic stress, antidepressants, neuroinflammation
MeSH terms
Animals, Antidepressive Agents, Cell Communication, Humans, Neuroglia, Neurons, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review